Dose Escalation Study Phase I/II of Umbilical and Cord Blood-Derived CAR-Engineered NK Cells in Conjunction in Patients With Relapsed/Refractory B-Lymphoid Malignancies

Trial Profile

Dose Escalation Study Phase I/II of Umbilical and Cord Blood-Derived CAR-Engineered NK Cells in Conjunction in Patients With Relapsed/Refractory B-Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; IC9/CAR.19/IL15-transduced-CB-NK-cells (Primary) ; Mesna; Rimiducid
  • Indications B cell lymphoma; B-cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 20 Apr 2017 Planned End Date changed from 1 May 2022 to 1 Jun 2022.
    • 20 Apr 2017 Planned primary completion date changed from 1 May 2022 to 1 Jun 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top